We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
+29.54%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$61.1M
AUM Growth
+$5.88M
Cap. Flow
-$7.51M
Cap. Flow %
-12.3%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$7.51M

Sector Composition

Rank Sector Weight
1 Healthcare 8.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$55.7M 91.25%
1,864,174
-304,427
-14% -$7.51M
ADMA icon
2
ADMA Biologics
ADMA
$1.94B
$5.3M 8.68%
1,433,304
– –
MBVX
3
DELISTED
MABVAX THERAPEUTICS HLDGS INC
MBVX
$37K 0.06%
8,903
– –

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Biomark Capital Management held 3 positions worth $61.1M, up 11% from $55.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Biomark Capital Management withdrew a net $7.51M in Q2 2017, reducing 1 holding. Its largest reduction was Juno Therapeutics, Inc., cutting an estimated $7.51M.

By sector, the portfolio is most concentrated in Healthcare at 8.7% of assets, down from 13% a quarter earlier.

  • Biomark Capital Management's biggest Q2 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $7.51M.
  • Biomark Capital Management's ten largest holdings make up 100% of its $61.1M portfolio in Q2 2017.
  • Biomark Capital Management opened 0 new positions and closed 0 in Q2 2017.
  • Biomark Capital Management's portfolio value rose 11% quarter-over-quarter to $61.1M.

Based on Biomark Capital Management's 13F filing for Q2 2017, filed 8 Aug 2017.